Jörg Westermann

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties
    Jörg Westermann
    Department of Hematology and Tumor Immunology, Charite, Campus Berlin Buch, Lindenberger Weg 80, Germany
    Cancer Immunol Immunother 52:194-8. 2003
  2. ncbi Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
    J Westermann
    Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine Berlin, Campus Virchow Klinikum and Campus Berlin Buch, Berlin, Germany
    Gene Ther 18:354-63. 2011
  3. ncbi Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome
    Jörg Westermann
    Department of Hematology and Oncology, Charite, University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    J Immunother 32:667-75. 2009
  4. ncbi Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
    Jörg Westermann
    Department of Haematology and Oncology, Charite, University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    Br J Haematol 137:297-306. 2007
  5. ncbi CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity
    J Westermann
    Department of Hematology, Charite University Medicine Berlin, Campus Berlin Buch, Berlin, Germany
    Cancer Gene Ther 14:523-32. 2007
  6. ncbi Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia
    Jörg Westermann
    Department of Haematology and Oncology, Charite University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    Br J Haematol 132:32-5. 2006
  7. ncbi CD52 is not a promising immunotherapy target for most patients with multiple myeloma
    Jörg Westermann
    Department of Hematology and Oncology, Charite University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    Int J Hematol 82:248-50. 2005
  8. ncbi T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia
    Jörg Westermann
    Department of Haematology and Oncology, Charite, University Medicine Berlin, Campus Virchow Clinic, Augustenburger Platz 1, 13353 Berlin, Germany
    Br J Haematol 125:213-6. 2004
  9. ncbi CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model
    Tam Nguyen-Hoai
    Department of Hematology, Oncology and Tumor Immunology, Charite, University Medicine Berlin, Campus Berlin Buch and Campus Virchow Klinikum, Germany
    J Gene Med 14:128-37. 2012
  10. ncbi Long-lasting remission of pulmonary metastases of renal cell cancer under IFN-beta therapy in a patient with multiple sclerosis
    Anne Florcken
    Department of Hematology and Oncology, Charite University Medicine Berlin, Campus Virchow Klinikum, Germany
    Onkologie 29:382-4. 2006

Collaborators

Detail Information

Publications11

  1. ncbi Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties
    Jörg Westermann
    Department of Hematology and Tumor Immunology, Charite, Campus Berlin Buch, Lindenberger Weg 80, Germany
    Cancer Immunol Immunother 52:194-8. 2003
    ..Our data indicate that cryopreserved aliquots of DC are suitable for clinical application in DC-based immunotherapy protocols...
  2. ncbi Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
    J Westermann
    Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine Berlin, Campus Virchow Klinikum and Campus Berlin Buch, Berlin, Germany
    Gene Ther 18:354-63. 2011
    ..Vaccination in minimal residual disease with concurrent depletion of regulatory cells might be one strategy to overcome this limitation...
  3. ncbi Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome
    Jörg Westermann
    Department of Hematology and Oncology, Charite, University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    J Immunother 32:667-75. 2009
    ..However, the study suggests that CD80/86+ T cells might have negative regulatory function under cytokine treatment and are possibly useful as a negative predictive marker for clinical response...
  4. ncbi Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
    Jörg Westermann
    Department of Haematology and Oncology, Charite, University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    Br J Haematol 137:297-306. 2007
    ..DC vaccination might be useful in CML as postremission therapy, i.e. after treatment with tyrosine kinase inhibitors...
  5. ncbi CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity
    J Westermann
    Department of Hematology, Charite University Medicine Berlin, Campus Berlin Buch, Berlin, Germany
    Cancer Gene Ther 14:523-32. 2007
    ..We conclude that CCL19 is an attractive adjuvant for DNA vaccination able to augment antitumor immunity and that this effect is partially caused by enhanced CD8+ T-cell recruitment...
  6. ncbi Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia
    Jörg Westermann
    Department of Haematology and Oncology, Charite University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    Br J Haematol 132:32-5. 2006
    ..CBA appears to be a new useful tool for the detection of leukaemia-reactive T cells...
  7. ncbi CD52 is not a promising immunotherapy target for most patients with multiple myeloma
    Jörg Westermann
    Department of Hematology and Oncology, Charite University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    Int J Hematol 82:248-50. 2005
    ..We conclude that CD52 is not a promising target for antibody-based therapies for most patients with multiple myeloma...
  8. ncbi T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia
    Jörg Westermann
    Department of Haematology and Oncology, Charite, University Medicine Berlin, Campus Virchow Clinic, Augustenburger Platz 1, 13353 Berlin, Germany
    Br J Haematol 125:213-6. 2004
    ..Our results suggest that the T cell repertoire contains bcr3/abl2-reactive T cells in CML patients who are in cytogenetic remission, but also in some healthy individuals...
  9. ncbi CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model
    Tam Nguyen-Hoai
    Department of Hematology, Oncology and Tumor Immunology, Charite, University Medicine Berlin, Campus Berlin Buch and Campus Virchow Klinikum, Germany
    J Gene Med 14:128-37. 2012
    ..In vivo, CCL19 is a key regulator for the interactions between DCs and T cells in regional lymph nodes...
  10. ncbi Long-lasting remission of pulmonary metastases of renal cell cancer under IFN-beta therapy in a patient with multiple sclerosis
    Anne Florcken
    Department of Hematology and Oncology, Charite University Medicine Berlin, Campus Virchow Klinikum, Germany
    Onkologie 29:382-4. 2006
    ..There is an ongoing debate whether hyperactivation of the immune system may convey protection against the development of cancer in MS patients...
  11. ncbi Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia
    Theo D Kim
    Clinic for Hematology and Oncology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Thyroid 20:1209-14. 2010
    ..Thyroid dysfunction is a well-known adverse effect of first-generation tyrosine kinase inhibitors (TKIs), like sunitinib. The aim of this study was to investigate the effect of second-generation TKIs on thyroid function...